Shi Shaoyan, Ou Xuehai, Liu Chao, Wen Hao, Jiang Ke
Department of Hand Surgery, Honghui Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Front Immunol. 2024 Aug 30;15:1464267. doi: 10.3389/fimmu.2024.1464267. eCollection 2024.
Immunoproteasome is a specialized form of proteasome which plays a crucial role in antigen processing and presentation, and enhances immune responses against malignant cells. This review explores the role of immunoproteasome in the anti-tumor immune responses, including immune surveillance and modulation of the tumor microenvironment, as well as its potential as a target for cancer immunotherapy. Furthermore, we have also discussed the therapeutic potential of immunoproteasome inhibitors, strategies to enhance antigen presentation and combination therapies. The ongoing trials and case studies in urology, melanoma, lung, colorectal, and breast cancers have also been summarized. Finally, the challenges facing clinical translation of immunoproteasome-targeted therapies, such as toxicity and resistance mechanisms, and the future research directions have been addressed. This review underscores the significance of targeting the immunoproteasome in combination with other immunotherapies for solid tumors and its potential broader applications in other diseases.
免疫蛋白酶体是蛋白酶体的一种特殊形式,在抗原加工和呈递中起关键作用,并增强针对恶性细胞的免疫反应。本综述探讨了免疫蛋白酶体在抗肿瘤免疫反应中的作用,包括免疫监视和肿瘤微环境的调节,以及其作为癌症免疫治疗靶点的潜力。此外,我们还讨论了免疫蛋白酶体抑制剂的治疗潜力、增强抗原呈递的策略和联合疗法。还总结了泌尿外科、黑色素瘤、肺癌、结直肠癌和乳腺癌正在进行的试验和病例研究。最后,阐述了免疫蛋白酶体靶向治疗临床转化面临的挑战,如毒性和耐药机制,以及未来的研究方向。本综述强调了将免疫蛋白酶体与其他免疫疗法联合用于实体瘤的重要性及其在其他疾病中更广泛应用的潜力。